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Abstract 24 
We quantified genome-wide patterns of lysine H3K27 acetylation (H3K27ac) in entorhinal 25 
cortex samples from Alzheimer’s disease (AD) cases and matched controls using chromatin 26 
immunoprecipitation and highly parallel sequencing (ChIP-seq). We observed widespread 27 
acetylomic variation associated with AD neuropathology, identifying 4,162 differential peaks 28 
(FDR < 0.05) between AD cases and controls. Differentially acetylated peaks were enriched 29 
in disease-related biological pathways and included regions annotated to genes involved in 30 
the progression of Aβ and tau pathology (e.g. APP, PSEN1, PSEN2, and MAPT), as well as 31 
regions containing variants associated with sporadic late-onset AD. Partitioned heritability 32 
analysis highlighted a highly-significant enrichment of AD risk variants in entorhinal cortex 33 
H3K27ac peak regions. AD-associated variable H3K27ac was associated with 34 
transcriptional variation at proximal genes including CR1, GPR22, KMO, PIM3, PSEN1 and 35 
RGCC. In addition to identifying molecular pathways associated with AD neuropathology, we 36 
present a framework for genome-wide studies of histone modifications in complex disease. 37 
  38 
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Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized by cognitive 39 
decline and memory loss that contributes substantially to the global burden of disease, 40 
affecting in excess of 26 million people worldwide1. The symptoms of AD are associated with 41 
progressive neuropathology in the neocortex, with regions surrounding the entorhinal cortex 42 
being particularly affected early in the disease2. These neuropathological hallmarks of AD 43 
include the extracellular deposition of neurotoxic amyloid-β (Aβ) in the form of amyloid 44 
plaques and an accumulation of intracellular neurofibrillary tangles composed of 45 
hyperphosphorylated tau3. Despite progress in understanding risk factors contributing to AD 46 
progression, the mechanisms involved in disease progression are not fully understood and 47 
long-term treatments, reversing the cellular disease process in the cortex, are elusive. 48 
 49 
There has been considerable success in identifying genetic risk factors for AD4. While 50 
autosomal dominant mutations in three genes (APP, PSEN1, and PSEN2) can explain early-51 
onset (< 65 years) familial AD, these account for only 1-5% of the total disease burden5. 52 
Most cases of AD are late-onset (> 65 years), non-Mendelian and highly sporadic, with 53 
susceptibility attributed to the action of highly prevalent genetic variants of low penetrance. 54 
In addition to the well-established risk associated with the APOE locus6 there has been 55 
notable success in identifying novel AD-associated variants capitalising on the power of 56 
genome-wide association studies (GWAS) in large sample cohorts; a recent large GWAS 57 
meta-analysis of AD, incorporating > 74,000 samples, identified 19 genome-wide significant 58 
risk loci for sporadic AD7. Despite these advances, little is known about the functional 59 
mechanisms by which risk variants mediate disease susceptibility.  60 
 61 
Increased understanding about the functional complexity of the genome has led to growing 62 
recognition about the likely role of non-sequence-based regulatory variation in health and 63 
disease. Building on the hypothesis that epigenomic dysregulation is important in the 64 
etiology and progression of AD neuropathology8, we and others recently performed the first 65 
genome-scale cross-tissue analyses of DNA methylation in AD identifying robust DNA 66 
methylation differences associated with AD neuropathology across multiple independent 67 
human post-mortem brain cohorts9,10. To date, however, no study has systematically 68 
examined other types of regulatory genomic modifications in AD. In this study, we focus on 69 
lysine H3K27 acetylation (H3K27ac), a robust mark of active enhancers and promoters that 70 
is strongly correlated with gene expression and transcription factor binding11. Interestingly, 71 
histone deacetylase (HDAC) inhibitors have been shown to ameliorate symptoms of 72 
cognitive decline and synaptic dysfunction in mouse models of AD12 and are promising 73 
targets for novel human AD treatments13. Despite this, investigations into global levels of 74 
histone acetylation in AD have thus far been inconclusive14-16 and no study has taken a 75 
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genome-wide approach. In fact, few studies have systematically profiled H3K27ac across 76 
large numbers of samples in the context of complex disease, and optimal methods for these 77 
analyses are still being developed17. 78 
 79 
In this study, we used chromatin immunoprecipitation combined with highly-parallel 80 
sequencing (ChIP-seq) to quantify levels of H3K27ac across the genome in post-mortem 81 
entorhinal cortex samples from AD patients and matched controls, incorporating cell-type-82 
specific DNA methylation and gene expression marks to control for cellular heterogeneity. 83 
We identify regulatory genomic signatures associated with AD, including variable H3K27ac 84 
across discrete regions annotated to genomic loci mechanistically implicated in the onset of 85 
both tau and amyloid pathology, associating many of these differences with variation in gene 86 
expression. This is the first study of variable H3K27ac yet undertaken for AD; in addition to 87 
identifying molecular pathways associated with AD neuropathology, we present a framework 88 
for genome-wide studies of this modification in complex disease. 89 
 90 
Results 91 
Genome-wide profiling of inter-individual variation in H3K27ac in the entorhinal cortex 92 
We generated high-quality H3K27ac ChIP-seq data using post-mortem entorhinal cortex 93 
tissue dissected from 47 elderly individuals (mean age = 77.43, SD = 9.66, range = 58-97) 94 
comprising both AD cases (n = 24, mean Braak stage = 6.00, SD = 0.00) and age-matched 95 
low pathology controls (n = 23, mean Braak stage = 1.30, SD = 1.11) (Supplementary 96 
Table 1). Raw H3K27ac ChIP-seq data is available for download from the Gene Expression 97 
Omnibus (GEO) (accession number GSE102538). Genome-wide SNP data was used to 98 
confirm that each of the samples included in our analysis was of Western European ancestry 99 
(Supplementary Fig. 1). After stringent quality control (QC) of the raw H3K27ac ChIP-seq 100 
data (see Methods), we obtained a mean of 30,032,623 (SD = 10,638,091) sequencing 101 
reads per sample, with no difference in read-depth between AD cases and controls (Welsh 102 
two-sample t-test, two-sided, n = 47 biologically independent samples, P = 0.93, average 103 
read count difference: 260,673, 95%-confidence interval (CI): -6,602,319-6,080,972, t(43.85) 104 
= -0.08; Supplementary Fig. 2). This represents, to our knowledge, the most extensive 105 
analysis of H3K27ac in the human entorhinal cortex yet undertaken. Using combined data 106 
from all 47 samples (see Methods) we identified 182,065 high confidence H3K27ac peaks; 107 
these are distributed across all 24 chromosomes (Supplementary Table 2) spanning a 108 
mean length of 983bp (SD = 682bp) with a mean distance between neighbouring peaks of 109 
15,536bp (SD = 116,040bp). We validated the identified peaks using two independent ChIP-110 
seq datasets: first, we obtained locations for cortex and cerebellum H3K27ac peaks from a 111 
recent analysis of autism and control brains17; second, we downloaded peak profiles for 112 
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multiple cell- and tissue-types from the NIH Epigenomics Roadmap Consortium18 (see 113 
Methods). As expected, there was a very high overlap between H3K27ac peaks called in 114 
these previous neocortical datasets and our ChIP-seq data, with a notably lower overlap with 115 
H3K27ac data from non-cortical tissues (Supplementary Fig. 3 and Supplementary Fig. 116 
4). For example, ~95% of BA9 H3K27ac peaks identified by Sun et al17 overlap our peaks, 117 
compared to ~77% of the cerebellum peaks identified in their experiment. Furthermore, 118 
samples profiled by the NIH Epigenomics Roadmap Consortium overlap our peaks in a 119 
tissue-specific manner with up to 97% overlap observed for H3K27ac profiles derived 120 
cortical tissues and much lower overlaps from non-brain tissues (22-47%). 121 
  122 
AD-associated differential acetylation in the entorhinal cortex 123 
We quantified read counts across every peak in each of the 47 individual samples included 124 
in the ChIP-seq study using HTSeq and employed a quasi-likelihood F test, implemented in 125 
the Bioconductor package EdgeR (see Methods for full description), to test for differences in 126 
H3K27ac between AD cases and low pathology controls. Our primary analysis model 127 
controlled for age at death and neuronal cell proportion estimates derived from DNA 128 
methylation data generated on the same samples (Supplementary Table 1, 129 
Supplementary Fig. 5). A total of 4,162 (2.3%) of the 182,065 peaks were characterized by 130 
AD-associated differential acetylation at a false discovery rate (FDR) < 0.05 (Fig. 1), with a 131 
significant enrichment of hypoacetylated AD-associated peaks (2,687 (1.5%)) compared to 132 
hyperacetylated AD-associated peaks (1,475 (0.8%)) (exact binomial test, n = 4,162 peaks, 133 
P < 1.00E-50, percentage of hypoacetylated peaks: 65%, 95%-CI: 63-66%) (Fig. 1). 134 
Because there are global differences in H3K27ac between males and females – the first 135 
principal component of variable H3K27ac was associated with sex in our data 136 
(Supplementary Fig. 6) – we undertook subsequent sensitivity analyses, confirming that 137 
4,157 (99.9%) of the 4,162 differentially acetylated peaks remain significantly differentially 138 
acetylated (FDR < 0.05) when additionally controlling for sex, with a near-perfect correlation 139 
in AD-associated H3K27ac differences between models (Pearson’s product-moment 140 
correlation, r = 1.00, P < 1.00E-50; Supplementary Fig. 7). Given the neurodegeneration 141 
and neural cell changes associated with AD pathology, we also quantified the levels of 142 
transcripts associated with five major brain cell types (ENO2 (neurons), OLIG2 143 
(oligodendrocytes), GFAP (astrocytes), CD68 (microglia) and CD34 (endothelial cells)) in 144 
our samples (see Methods). As expected, expression of the neuronal gene ENO2 was 145 
correlated with the neuronal cell proportion estimates derived from DNA methylation data 146 
(Supplementary Fig. 8) and found to be reduced in AD samples (linear regression, n = 47 147 
biologically independent samples, P = 0.023, β = -0.54, F(3,43) = 3.23) (Supplementary 148 
Fig. 8, Supplementary Fig. 9 and Supplementary Table 3). We also identified elevated 149 
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expression of CD34 (n = 47 biologically independent samples, P = 0.029, β = 0.76, F(3,44) = 150 
7.07), CD68 (n = 46 biologically independent samples, P = 0.012, β = 0.53, F(3,42) = 7.25), 151 
and GFAP (n = 47 biologically independent samples, P = 0.003, β = 0.76, F(3,44) = 3.48) in 152 
our AD cases (Supplementary Fig. 9 and Supplementary Table 3), reflecting results from 153 
previous studies19,20. Post-hoc analyses of our AD-associated peaks using models 154 
controlling for levels of these five cell-types showed that effects remained highly correlated 155 
with those from our original model (Pearson’s product-moment correlations with results from 156 
models controlling for i) ENO2: r = 0.99, P < 1.00E−50; ii) OLIG2: r = 0.99, P < 1.00E−50; iii) 157 
GFAP: r = 0.99, P < 1.00E−50; iv) CD68: r = 0.99, P < 1.00E−50; v) CD34: r = 0.99, P < 158 
1.00E−50; and vi) all cell markers combined: r = 0.98, P < 1.00E−50), indicating that the AD-159 
associated differences in H3K27ac are robust to cell-type heterogeneity (Supplementary 160 
Fig. 10). Finally, for each sample we also calculated standard ENCODE ChIP-seq quality 161 
metrics (see Methods) and included these as post-hoc covariates in our analyses; again 162 
AD-association effect-sizes remained highly correlated with those estimated from our 163 
original model (Pearson’s product-moment correlation, r = 0.95, P < 1.00E−50).   164 
 165 
UCSC Genome Browser tracks showing H3K27ac levels in AD cases and controls, in 166 
addition to association statistics, across the genome can be accessed at 167 
https://epigenetics.essex.ac.uk/AD_H3K27ac/. The ten top-ranked hyper- and 168 
hypoacetylated peaks associated with AD are shown in Table 1, with a complete list given in 169 
Supplementary Table 4 (hyperacetylated peaks) and Supplementary Table 5 170 
(hypoacetylated peaks). P values for sex, cell-type expression and quality metric controlled 171 
models at each of the 4,162 differentially acetylated peaks are reported in Supplementary 172 
Table 4 and Supplementary Table 5. Peaks were subsequently annotated to genes using 173 
an approach that takes into account the strength of proximal and distal DNA-binding events 174 
(see Methods). In total, differentially-acetylated peaks were annotated to 4,039 genes 175 
(hyperacetylated peaks: 1,728 genes; hypoacetylated peaks: 2,528 genes). The most 176 
significant AD-associated hyperacetylated peak (chr13: 112101248-112102698; P = 2.04E-177 
08; log fold change = 0.93) is annotated to both SOX1 and TEX29 on chromosome 13 (Fig. 178 
2, Table 1). Of note, H3K27ac data from the Epigenomics Roadmap Consortium show that 179 
this region is characterized by brain-specific enhancer activity (Supplementary Fig. 11). 180 
The most significant AD-associated hypoacetylated peak (chr7: 64011549-64012825; P = 181 
1.66E-08; log fold change = -0.86) is located within intron 1 of ZNF680 on chromosome 7 182 
(Fig. 3, Supplementary Fig. 11, Table 1). Global clustering of samples by normalized read 183 
counts across all hyper- and hypoacetylated peaks (FDR < 0.05) indicated that, as expected, 184 
samples group primarily by disease status (Fig. 4). AD-associated differentially acetylated 185 
peaks (FDR < 0.05) are significantly longer (Welsh two-sample t-test, two-sided, P < 1.00E-186 
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50, average difference in length = 320.02bp, 95%-CI: 298-342bp, t(4340.5) = 28.70) and 187 
characterized by higher read-depths (CPM; P < 1.00E-50, average difference in log CPM = 188 
0.46, 95%-CI: 0.42-0.50, t(4463.7) = 24.33) than non-significant peaks (Supplementary Fig. 189 
12). Of note, within AD-associated peaks, hypoacetylated peaks are significantly longer (P = 190 
5.66E-31, average difference in length = 331.23bp, 95%-CI: 288-374bp, t(3303.8) = 15.17) 191 
and have higher read-depths (P = 2.69E-50, average difference in log CPM = 0.45, 95%-CI: 192 
0.37-0.52, t(3111.4) = 11.70) compared to hyperacetylated peaks. We used RSAT to identify 193 
enriched transcription factor binding motifs located within AD-associated differentially 194 
acetylated peaks (see Methods), observing a significant enrichment of binding motifs for 195 
specificity protein 1 (Sp1) (binomial test, P < 1.00E-50), a transcription factor that has been 196 
implicated in the immune response, apoptosis and chromatin remodelling, amongst AD-197 
hyperacetylated peaks (FDR < 0.05). Of note, previous publications have reported 198 
dysregulated expression of Sp1 and its co-localization with neurofibrillary tangles in AD21,22. 199 
 200 
Differential H3K27ac is observed in regulatory regions annotated to genes previously 201 
implicated in both tau and amyloid neuropathology 202 
One of the top-ranked AD-associated hyperacetylated peaks is located proximal to the gene 203 
encoding microtubule associated protein tau (MAPT) (chr17: 43925717-43927482; P = 204 
7.01E-07; log fold change = 0.71; Table 1), which is widely expressed in the nervous system 205 
where it functions to promote microtubule assembly and stability. Tau is believed to play a 206 
key role in AD neuropathology, with hyperphosphorylation of the tau protein precipitating the 207 
neurofibrillary tangles associated with the pathogenesis of AD23,24. Closer inspection of the 208 
region around this AD-associated peak highlighted an extended cluster of six hyper-209 
acetylated H3K27ac peaks (FDR < 0.05) spanning 36kb (chr17: 43925717 - 43961546) 210 
located within a MAPT antisense transcript (MAPT_AS1) ~10kb upstream of the MAPT 211 
transcription start site (Fig. 5; Supplementary Table 6). H3K27ac ChIP-seq data from the 212 
NIH Epigenomics Roadmap Consortium show that this region is characterized by CNS-213 
related H3K27ac signatures (Fig. 5), with ChromHMM25 identifying the region as an active 214 
chromatin domain in brain comprised of enhancers and blocks of weak transcription 215 
(Supplementary Fig. 13). Strikingly, AD-associated differentially-acetylated peaks were 216 
also found in the vicinity of other genes known to play a direct mechanistic role in AD. We 217 
identified a significantly hypoacetylated peak (chr21: 27160993 - 27161475; P = 3.94E-04; 218 
log fold change = -0.72) on chromosome 21, located ~100kb downstream of the amyloid 219 
precursor protein gene (APP), which encodes the precursor molecule to Aβ, the main 220 
component of amyloid plaques26-28 (Supplementary Fig. 14). We also identified significant 221 
hyperacetylation in the vicinity of the presenilin genes PSEN1 and PSEN2, which encode 222 
integral components of the gamma secretase complex and play a key role in generation of 223 
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Aβ from APP29. In PSEN1 we found significantly elevated H3K27ac across a peak within 224 
intron 6 (chr14: 73656445 - 73656860; P = 3.44E-04; log fold change = 0.68; 225 
Supplementary Fig. 15). In PSEN2 we identified consistent hyperacetylation in AD cases 226 
across nine H3K27ac peaks (FDR < 0.05) spanning a ~57 kb region upstream of the 227 
transcription start-site (chr1: 226957424 - 227014019; Fig. 6, Supplementary Fig. 13 and 228 
Supplementary Table 7). Of note, highly-penetrant mutations in APP, PSEN1, and PSEN2 229 
are associated with familial forms of early-onset AD30. We used a hypergeometric test (one-230 
sided) to confirm a significant enrichment of AD-associated differential acetylation 231 
associated with i) familial AD genes (APP, PSEN1, PSEN2): 11 FDR-significant peaks from 232 
a total of 163 annotated peaks, P = 0.001; ii) the MAPT locus: six FDR-significant peaks 233 
from a total of 36 annotated peaks, P = 1.54E-04; and iii) all four AD pathology genes 234 
combined: 17 FDR-significant peaks from a total of 199 annotated peaks, P = 4.05E-06. The 235 
identification of altered regulation of these loci in late-onset sporadic AD brain further 236 
supports a key role for altered amyloid processing in the onset of neuropathology.  237 
 238 
Genetic risk for AD is enriched in entorhinal cortex H3K27ac peaks, with specific 239 
differentially-acetylated peaks overlapping known AD GWAS regions 240 
Using the AD GWAS meta-analysis results from Lambert and colleagues7 we performed LD  241 
Score regression to quantify the proportion of SNP heritability accounted for by variants 242 
colocalizing with the entorhinal cortex H3K27ac peaks identified in this study (see Methods). 243 
Of the total heritability across all SNPs derived from stage 1 of the GWAS meta-analysis 244 
results (h2 = 0.0789), a large proportion (38.3%, h2 = 0.0302 (95%-CI: 0.0126 - 0.0478)) is 245 
accounted for by variants within H3K27ac peaks, representing a significant enrichment 246 
(enrichment = 1.10 (95%-CI: 1.05 - 1.15) (Supplementary Table 8), and indicating that AD 247 
risk alleles are preferentially located in regions of regulatory/enhancer function in the brain. 248 
We next identified instances where there is an overlap between AD-associated differential 249 
H3K27ac and genomic regions harbouring risk variants. Briefly, we defined linkage-250 
disequilibrium (LD) blocks around the genome-wide significant (P < 5.0E-08) GWAS variants 251 
identified by the stage 1 meta-analysis by Lambert and colleagues7 (Supplementary Table 252 
9), which contained a total of 292 overlapping entorhinal cortex H2K27ac peaks (see 253 
Methods). Two of the 11 GWAS LD blocks contained significant AD-associated H3K27ac 254 
peaks (FDR < 0.05), although there was no overall enrichment of AD-associated differential 255 
acetylation at the 292 peaks (Wilcoxon rank-sum test with continuity correction, n= 182,065 256 
peaks, P = 0.364, W = 27354000). Two peaks of AD-associated hyperacetylation were 257 
located within a GWAS region on chromosome 1, mapping to the gene body of CR1 (chr1: 258 
207753457-207753813; P = 1.15E-06; log fold change = 0.99 and chr1: 207754916-259 
207756572; P = 5.40E-04; log fold change = 0.56; Supplementary Fig. 16). CR1 encodes a 260 
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transmembrane glycoprotein expressed in microglia with a role in the innate immune 261 
system, promoting phagocytosis of immune complexes and cellular debris, in addition to 262 
Aβ31-33. Two other AD-associated differentially acetylated peaks were found to be located 263 
within a GWAS region on chromosome 19, including a hyperacetylated peak 264 
(chr19:45394441- 45395396; P = 2.13E-04; log fold change = 0.48) mapping to the gene 265 
body of TOMM40 in the immediate vicinity of APOE (Supplementary Fig. 17). Another 266 
H3K27ac peak in this LD block was significantly hypoacetylated in AD (chr19: 45639588- 267 
45641733; P = 7.65E-04; log fold change = -0.33), mapping to intron 1 of PPP1R37. 268 
 269 
AD-associated differentially-acetylated peaks are enriched for functional processes related 270 
to neuropathology 271 
We next calculated statistical enrichments for ontological annotations amongst our AD-272 
associated peaks (see Methods), interrogating gene ontologies for molecular function and 273 
biological processes as well as human diseases (hypergeometric test; see Supplementary 274 
Table 10 and Supplementary Fig. 18, with a full list of significant ontologies in 275 
Supplementary Tables 11-16). Multiple ontological categories associated with AD 276 
progression and pathology were identified as being enriched (FDR < 0.05) amongst 277 
hyperacetylated peaks, including “lipoprotein particle binding”6,34 (P = 1.10E-06), “beta-278 
amyloid metabolic process”23 (P = 4.94E-08), “response to hypoxia”35,36 (P = 3.17E-14), and 279 
“Pick’s disease” (P = 2.93E-07), a form of fronto-temporal dementia also characterized by 280 
tau pathology24,37. Amongst hypoacetylated peaks we observed an enrichment of categories 281 
related to neurotransmitter-functions, including “GABA receptor activity”38 (P = 2.70E-07) as 282 
well as categories related to neuronal transmission and synapses, such as “protein location 283 
to synapse” (P = 7.86E-09). Because the observed enrichment for functional processes 284 
related to neuropathology might reflect underlying cellular heterogeneity between samples 285 
we repeated these analyses using only peaks that were significantly differentially acetylated 286 
(FDR < 0.05) in our model controlling for all five neural cell types. Our sensitivity analyses 287 
confirmed that most AD-related pathway enrichments were robust to cellular heterogeneity 288 
including “lipoprotein particle binding” (P = 4.36E-05), “apolipoprotein binding” (P = 1.24E-289 
04), “response to hypoxia” (P = 5.28E-08), “beta-amyloid metabolic process” (P = 1.61E-05) 290 
and “Pick’s disease” (P = 4.04E-05). Although there is some overlap between the genes in 291 
each pathway (Supplementary Table 10), and the ontological categories we identify are not 292 
totally independent, these results indicate a striking enrichment of AD-related pathways in 293 
both hyper- and hypoacetylated regions. 294 
 295 
AD-associated variable H3K2ac is associated with the expression of nearby genes. 296 
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We next quantified the expression of selected cortex-expressed genes located proximal to 297 
top-ranked differentially-acetylated peaks (RGCC, PIM3, ANKRD17, ZNF680, GPR22, and 298 
KMO) in an extended set of 95 entorhinal cortex samples (average age = 81.3, SD = 9.3, 299 
range = 58-99) from both AD cases (n = 67, mean Braak stage = 5.4, SD = 0.8) and age-300 
matched low pathology controls (n = 28, mean Braak stage = 1.5, SD = 1.1) 301 
(Supplementary Table 1). The expression of RGCC and PIM3, both located proximal to 302 
hyperacetylated peaks, was found to be significantly up-regulated in AD cases (linear 303 
regression; RGCC: n = 94 biologically independent samples, P = 0.002, β = 0.44, F(3,92) = 304 
25.78; PIM3: n = 95 biologically independent samples, P = 9.52E-05, β = 0.57, F(3,92) = 305 
2.88) (Fig. 7). Furthermore, the expression of GPR22 and KMO, both located proximal to 306 
hypoacetylated peaks, was found to be significantly down-regulated in AD cases (GPR22: n 307 
= 95 biologically independent samples, P = 0.005, β = -0.71, F(3,90) = 12.09; KMO: n = 60 308 
biologically independent samples, P = 0.006, β = -0.96, F(3,57) = 2.77) (Fig. 7). Of note, the 309 
expression of these four transcripts was positively associated with levels of H3K27ac (i.e. 310 
higher H3K27ac is associated with a reduced delta Ct value) across their proximal AD-311 
associated differentially acetylated peaks in samples included in our ChIP-seq dataset 312 
(quasi-likelihood F test, two-sided; RGCC: n = 47 biologically independent samples, P = 313 
0.123, log fold change = -0.22; PIM3: n = 47 biologically independent samples, P = 0.023, 314 
log fold change = -0.35; GPR22: n = 46 biologically independent samples, P = 1.1E-04, log 315 
fold change = -0.38; KMO: n = 33 biologically independent samples, P = 0.050, log fold 316 
change = -0.15) (Supplementary Fig. 19). Interestingly, previous studies have implicated 317 
dysregulation of RGCC39, GPR2240 and KMO41 in AD. In contrast, ANKRD17 and ZNF680 318 
were not found to be differentially expressed in AD cases (Supplementary Table 17); of 319 
note H3K27ac enhancer domains often reside considerable distance from their target gene42 320 
and effects on more distal transcripts cannot be excluded. We also quantified the expression 321 
of six genes - previously implicated in tau and amyloid pathology or from GWAS – that were 322 
annotated to differentially acetylated peaks (MAPT, PSEN1, PSEN2, APP, TOMM40 and 323 
CR1) (Supplementary Table 18). We found significantly higher expression of PSEN1 (linear 324 
regression, n = 95 biologically independent samples, P = 4.91E-04, β = 0.45, F(3,92) = 4.98) 325 
and CR1 (n = 91 biologically independent samples, P = 0.001, β = 0.72, F(3,88) = 5.89) in 326 
AD cases (Fig. 7), reflecting the hyperacetylated peaks observed in the vicinity of these 327 
genes, with the expression of both transcripts being robustly associated with levels of 328 
H3K27ac across their proximal AD-associated differentially acetylated peaks in samples 329 
included in our ChIP-seq dataset (quasi-likelihood F test, two-sided; PSEN1: n = 47 330 
biologically independent samples, P = 0.011, log fold change = -0.42; CR1: n = 45 331 
biologically independent samples, peak 1: P = 0.002, log fold change = -0.37;peak 2: P = 332 
0.001, log fold change =-0.31) (Supplementary Fig. 20). In contrast, the expression of 333 
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MAPT (linear regression, n = 94 biologically independent samples, P = 0.783, β = -0.03, 334 
F(3,91) = 17.19), PSEN2 (n = 88 biologically independent samples, P = 0.913, β = 0.01, 335 
F(3,84) = 0.64), APP (n = 95 biologically independent samples, P = 0.078, β = -0.22, F(3,92) 336 
= 2.02) and TOMM40 (n = 94 biologically independent samples, P = 0.286, β = -0.09, 337 
F(3,90) = 3.14) was not significantly different between AD cases and controls, or associated 338 
with proximal levels of H3K27ac (Supplementary Table 18).  339 
 340 
Integrative analysis of DNA and histone modifications reveal unique distributions of DNA 341 
modifications across regions of differential acetylation  342 
Our previous work identified cortex-specific variation in DNA methylation (5mC) robustly 343 
associated with AD pathology9,10. We were therefore interested in exploring the relationship 344 
between H3K27ac and both 5mC and another DNA modification – DNA hydroxymethylation 345 
(5hmC), which is enriched in the brain and believed to play an important role in neuronal 346 
function, learning and memory43,44 - in our samples. Both modifications were profiled using 347 
DNA isolated from the same entorhinal cortex samples using oxidative bisulfite (oxBS) 348 
conversion in conjunction with the Illumina 450K HumanMethylation array (“450K array”) 349 
(see Methods). Focusing on Illumina 450K sites within 1kb of our H3K27ac peaks, we 350 
identified 268,477 probe-peak pairs (comprising of 232,233 unique 450K array probes and 351 
62,714 (34.45% of total) unique H3K27ac peaks). 6,838 probes mapped to within 1kb of an 352 
AD-associated differentially acetylated peak (FDR < 0.05; n = 1,649 unique peaks (616 353 
hyperacetylated, 1,033 hypoacetylated)). First, we tested for differential 5mC and 5hmC 354 
associated with AD at these probes, controlling for age at death and cell-type proportion 355 
estimates. None of the differences in 5mC (minimum P = 2.47E-03) or 5hmC (minimum P = 356 
1.53E-03) were significant when correcting for multiple testing (n = 6,838 tests; P < 7.31E-357 
05), indicating that there is little direct overlap in AD-associated variation in H3K27ac and 358 
DNA modifications. Comparing effect sizes at these 6,838 peak–probe pairs identified no 359 
evidence for an overall correlation between AD-associated H3K27ac and 5mC differences 360 
(Pearson’s product-moment correlation, r = 0.009, P = 0.443; Supplementary Fig. 21) with 361 
a small, but significant, negative correlation for 5hmC (Pearson’s product-moment 362 
correlation r = -0.045, P = 1.63E-04; Supplementary Fig. 21). As expected, both DNA 363 
modifications are significantly lower in the vicinity of H3K27ac peaks compared to the 364 
genome-wide 450K array background (Welsh two-sample t-test, two-sided; 5mC: P < 1.00E-365 
50, average beta difference = 12.47%, 95%-CI: 12.35-12.59%, t(551560) = 195.94; 5hmC: P 366 
= 3.61E-30, average beta difference = 0.16%, 95%-CI: 0.13-0.19%, t(494170) = 10.99; 367 
Supplementary Fig. 21), consistent with H3K27ac being localized at active enhancers and 368 
promoters. We next explored the relationship between variable 5mC and H3K27ac in our 369 
samples, finding that data for 439 probe-peak pairs (corresponding to 419 unique 450K 370 
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array probes and 319 unique H3K27ac peaks) were significantly correlated (FDR < 0.05) 371 
(Supplementary Table 19); 414 (94.31%) of the significant correlations were negative, with 372 
higher H3K27ac being associated with lower 5mC. Of note, 12 of the significant associations 373 
between H3K27ac and 5mC involve an AD-associated differentially acetylated peak 374 
(Supplementary Table 20 and Supplementary Fig. 22). Interestingly, we identified an AD-375 
associated differentially acetylated peak (chr4:1044452- 1044737, quasi-likelihood F test, 376 
two-sided, P = 0.001, log fold change = 0.83) annotated to FGFRL1 and RNF212 at which 377 
H3K27ac is correlated with 5mC at three specific 450K array probes (Pearson’s product-378 
moment correlation, n = 42 biologically independent samples; cg04016957, r = -0.66, P = 379 
1.66E-07; cg04106633, r = -0.71, P = 1.36E-07; cg21130718, r = -0.70, P = 2.98E-07). 380 
 381 
Discussion 382 
We quantified H3K27ac across the genome in post-mortem entorhinal cortex tissue 383 
samples, identifying widespread AD-associated acetylomic variation. Strikingly, differentially 384 
acetylated peaks were identified in the vicinity of genes implicated in both tau and amyloid 385 
neuropathology as well as genomic regions containing variants associated with sporadic 386 
late-onset AD. Partitioned heritability analysis highlighted a highly-significant enrichment of 387 
AD risk variants in entorhinal cortex H3K27ac peak regions. Finally, targeted gene 388 
expression analysis showed that variable H3K27ac is associated with transcriptional 389 
variation at proximal genes including CR1, GPR22, KMO, PIM3, PSEN1 and RGCC. This is 390 
the first study of variable H3K27ac yet undertaken for AD; in addition to identifying molecular 391 
pathways associated with AD neuropathology, we introduce a framework for genome-wide 392 
studies of this modification in complex disease.  393 
 394 
Given its close relationship with transcriptional activation, for example via the mediation of 395 
transcription factor binding, the identification of AD-associated variation in H3K27ac 396 
highlights potential novel regulatory genomic pathways involved in disease etiology. We find 397 
widespread alterations in H3K27ac associated with AD, including in the vicinity of several 398 
genes known to be directly involved in the progression of Aβ and tau pathology23,45 (APP, 399 
PSEN1, PSEN2, MAPT), supporting the notion that dysregulation of both pathways is 400 
involved in the onset of AD. Interestingly, although our study assessed brains from donors 401 
affected by sporadic late-onset AD, we identify widespread altered H3K27ac in the vicinity of 402 
genes implicated in familial early-onset AD. This indicates that these two forms of the 403 
disease may share common pathogenic pathways and mechanisms. Given that histone-404 
acetylation modifiers are amongst the most promising target pharmacological treatments of 405 
AD13,46, the identification of altered H3K27ac in AD is important, giving clues as to which 406 
genes and pathways may be involved. 407 
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 408 
Our study has a number of limitations, which should be considered when interpreting these 409 
results. First, we undertook ChIP-seq using bulk entorhinal cortex samples comprising a mix 410 
of neuronal and non-neuronal cell-types. This is an important limitation in epigenomic 411 
studies of a disease characterized by cortical neuronal loss. However, we were able to 412 
control, in part, for variation in neuronal proportions in our samples by i) deriving neuronal 413 
proportion estimates for each sample using DNA methylation data generated on the same 414 
tissue samples47 and ii) quantifying the expression of levels of transcripts associated with 415 
five major brain cell types (ENO2 (neurons), OLIG2 (oligodendrocytes), GFAP (astrocytes), 416 
CD68 (microglia) and CD34 (endothelial cells)) in our samples. Despite these efforts to 417 
control for cellular heterogeneity, however, it is plausible that we have not selected the most 418 
optimal cell type-specific markers for this purpose, especially because certain markers 419 
reflect both the activity and abundance of specific cell types (e.g. CD68 in microglia). 420 
Second, our cross-sectional analysis of post-mortem brain tissue makes direct causal 421 
inference difficult, and it is likely that many of the changes in H3K27ac we observe result 422 
from the AD pathology itself. In this regard, however, it is interesting that we see disease-423 
associated H3K27ac in the vicinity of genes causally implicated in familial forms of AD and 424 
we were able to show that genes annotated to specific differentially acetylated peaks 425 
showed disease-associated gene expression differences in the same samples. Third, 426 
although our targeted gene expression analyses identified differences at a number of genes 427 
annotated to differentially-acetylated peaks, we cannot make any conclusions about the 428 
relationship between H3K27ac and gene expression at a genome-wide level. Fourth, we 429 
have assessed a relatively small number of samples. In this light, it is notable that we 430 
identify substantial differences between AD cases and controls, with disease-associated 431 
regulatory variation in genes and functional pathways known to play a role in the onset and 432 
progression of neuropathology. The clear clustering between patients and controls at our 433 
differentially acetylated peaks suggests that, despite a complex and heterogeneous etiology, 434 
AD may be characterized by a common molecular pathology in the entorhinal cortex, 435 
reflecting neuropathological analyses. Furthermore, our differential gene expression 436 
analyses of transcripts associated with selected differentially acetylated peaks highlighted 437 
consistent differences in an extended set of samples. Fifth, chromatin architecture and 438 
transcriptional regulation is influenced by a multitude of epigenetic mechanisms. Although 439 
profiling H3K27ac can provide relatively robust information about transcriptional activity, it 440 
represents only one of perhaps ~100 post-translational modifications occurring at > 60 441 
histone amino-acid residues regulating genomic function. A recent study, for example, 442 
identified dysregulation of H4K16ac in AD brain48. Finally, we annotated genes to H3K27ac 443 
peaks by assigning genes to regulatory regions within 5kb upstream and 1kb downstream of 444 
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the transcription start site (proximal) or up to 1000kb for distal interactions, although such an 445 
approach may not be optimal. Recent chromatin conformation studies suggest that distal 446 
enhancers do not necessarily regulate the most proximal gene49; although no detailed Hi-C 447 
data currently exists for adult human cortex, the generation of these data will enable us to 448 
further interrogate the functional consequences of the AD-associated differences reported 449 
here. 450 
 451 
In summary, we provide compelling evidence for widespread acetylomic dysregulation in the 452 
entorhinal cortex in AD. Our data suggest that regulatory variation at multiple loci, including 453 
in the vicinity of several known AD risk genes – APP, CR1, MAPT, PSEN1, PSEN2 and 454 
TOMM40 – is robustly associated with disease, supporting the notion of common molecular 455 
pathways in both familial and sporadic AD. In addition to identifying molecular pathways 456 
associated with AD neuropathology, we present a framework for genome-wide studies of 457 
histone modifications in complex disease, integrating our data with results obtained from 458 
genome-wide association studies as well as other epigenetic marks profiled on the same 459 
samples. 460 
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Figure 1. Variable H3K27ac associated with Alzheimer’s disease (AD) in the entorhinal 630 
cortex. (a) Manhattan plot showing the raw -log10 P value for differential H3K27ac against 631 
chromosomal location from the EdgeR quasi-likelihood F test (two-sided), controlling for age 632 
and derived neuronal proportion (n = 47 biologically independent samples). Variation in 633 
H3K27ac at 4,162 peaks was identified as being associated with AD (red line = FDR < 0.05). 634 
(b) Volcano plot showing the raw -log10 P value and log fold change for differential H3K27ac 635 
at each entorhinal cortex H3K27ac peak (n = 47 biologically independent samples, red line = 636 
FDR < 0.05). Of the AD-associated peaks, 1,475 (35%, 95%-CI: 34-37%) are 637 
hyperacetylated (higher H3K27ac) in AD and 2,687 (65%, 95%-CI: 63-66%) are 638 
hypoacetylated (lower H3K27ac) in AD (exact binomial test, n = 4,162 peaks, P < 1.00E-50). 639 
 640 
Figure 2. The top-ranked AD-associated hyperacetylated peak is annotated to SOX1 641 
and TEX29 on chromosome 13. Shown are (a) normalized read counts and (b) a regional 642 
track of H3K27ac ChIP-seq data showing weighted mean AD (n = 24 biologically 643 
independent samples) and control (n = 23 biologically independent samples) ChIP-seq 644 
coverage per million reads in addition to an overlay track highlighting the acetylation 645 
differences. (a) The most significant AD-hyperacetylated peak is characterized by a 646 
consistent increase in H3K27ac in patients (quasi-likelihood F test, two-sided, P = 2.04E-08, 647 
FDR = 0.002, log fold change = 0.93). The center line of the boxplot shows the median, the 648 
outer hinges correspond to the 25th and 75th percentile, respectively, and the whiskers 649 
extend to the most extreme observed value within 1.5 times the interquartile range (IQR) 650 
from the two hinges. (b) This peak is located on chromosome 13 and annotated to both 651 
SOX1 and TEX29. Also shown is the location of all entorhinal cortex H3K27ac peaks in this 652 
region, hyper- and hypoacetylated peaks (FDR < 0.05), as well as the -log 10 P value and 653 
log fold change of normalized read count differences for each peak calculated using a quasi-654 
likelihood F test. 655 
 656 
Figure 3. The top-ranked AD-associated hypoacetylated peak is located in intron 1 of 657 
ZNF680 on chromosome 7. Shown are (a) normalized read counts and (b) a regional track 658 
of H3K27ac ChIP-seq data showing weighted mean AD (n = 24 biologically independent 659 
samples) and control (n = 23 biologically independent samples) ChIP-seq coverage per 660 
million reads in addition to an overlay track highlighting the acetylation differences. (a) The 661 
most significant AD-hypoacetylated peak (quasi-likelihood F test, two-sided, P = 1.66E-08, 662 
FDR = 0.002) is characterized by a consistent decrease in H3K27ac in cases (log fold 663 
change = -0.86). The center line of the boxplot shows the median, the outer hinges 664 
correspond to the 25th and 75th percentile, respectively, and the whiskers extend to the most 665 
extreme observed value within 1.5 times the IQR from the two hinges. (b) This peak is 666 
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located in intron 1 of ZNF680 on chromosome 7. Also shown is the location of all entorhinal 667 
cortex H3K27ac peaks in this region, hyper- and hypoacetylated peaks (FDR < 0.05), as well 668 
as the -log 10 P value and log fold change of normalized read count differences for each 669 
peak calculated using a quasi-likelihood F test. 670 
 671 
Figure 4. Clustering of AD and low pathology control samples by H3K27ac levels at 672 
differentially acetylated peaks. (a) A heatmap, clustering samples (n = 47 biologically 673 
independent samples) by normalized read counts in all 1,475 significant AD hyperacetylated 674 
peaks (FDR < 0.05), generates three distinct groups: one comprised of controls only (group 675 
1, n = 13 biologically independent samples), a pure group of cases (group 2, n = 20 676 
biologically independent samples), and a mixed group containing both cases and controls 677 
(group 3, n = 14 biologically independent samples). Controls grouped together with cases in 678 
group 3 (n = 10 biologically independent samples) are characterized by significantly 679 
decreased neuronal proportion estimates, compared to those in the pure control group 1 680 
(Welsh two sample t-test, two-sided, P = 7.10E-04, mean reduction in estimated neuronal 681 
proportion (%) = 15%, 95%-CI: 7-23%, t(19.81) = 4.00). (b) A heatmap, clustering samples 682 
by all 2,687 significant AD hypoacetylated peaks (FDR < 0.05), divides the samples into two 683 
main groups: group 1 (n = 17 biologically independent samples) is composed mainly of 684 
controls, whereas group 2 (n = 30 biologically independent samples) contains more cases 685 
than controls. Interestingly, controls classified into group 2 are characterized by lower 686 
neuronal proportion estimates than those in group 1 (Welsh two sample t-test, two-sided, n = 687 
23 biologically independent samples, P = 0.004, mean reduction in neuronal proportion (%) 688 
= 14%, 95%-CI: 5-23%, t(15.85) = 3.41). The clustering defined by hyper- or hypoacetylated 689 
peaks is not significantly associated with sex (n = 47 biologically independent samples; 690 
hyperacetylated cluster: chi-square test, P = 0.763, χ2(2) = 0.54; hypoacetylated cluster: chi-691 
square test with Yates’ continuity correction, P = 0.269, χ2(1) = 1.22) or age at death (n = 47 692 
biologically independent samples; hyperacetylated cluster: linear regression, P = 0.827, 693 
F(2,44) = 0.19; hypoacetylated cluster: Welsh two-sample t-test, two-sided, P = 0.580, mean 694 
age difference =  -1.59 years, 95%-CI: -7.36-4.18 years, t(37.20) = -0.56). 695 
 696 
Figure 5. A region annotated to MAPT spanning six H3K27ac peaks is characterized 697 
by significant hyperacetylation in AD. A cluster of nine H3K27ac peaks was identified on 698 
chromosome 17. All nine peaks are hyperacetylated in cases (quasi-likelihood F test, two-699 
sided, n = 47 biologically independent samples, mean log fold change = 0.46; 700 
Supplementary Table 5). (a) For six of the nine peaks this increase in H3K27ac associated 701 
with AD is significant (FDR < 0.05). The center line of the boxplot shows the median, the 702 
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outer hinges correspond to the 25th and 75th percentile, respectively, and the whiskers 703 
extend to the most extreme observed value within 1.5 times the interquartile range (IQR) 704 
from the two hinges.  (b) The region is located ~10kb upstream of MAPT and is (c) 705 
characterized by brain specific H3K27ac profiles. The boundaries of the significantly 706 
differentially acetylated peak region are highlighted in red. 707 
 708 
Figure 6. A region annotated to PSEN2 spanning nine H3K27ac peaks is characterized 709 
by significant hyperacetylation in AD. A cluster of 14 H3K27ac peaks was identified on 710 
chromosome 1. All 14 peaks are hyperacetylated in cases (quasi-likelihood F test, two-711 
sided, n = 47 biologically independent samples, mean log fold change = 0.52; 712 
Supplementary Table 6). (a) For nine of the 14 peaks this increase in H3K27ac associated 713 
with AD is significant (FDR < 0.05). The center line of the boxplot shows the median, the 714 
outer hinges correspond to the 25th and 75th percentile, respectively, and the whiskers 715 
extend to the most extreme observed value within 1.5 times the interquartile range (IQR) 716 
from the two hinges. (b) The region is located ~44kb upstream of PSEN2 and is (c) 717 
characterized by predominantly brain-specific H3K27ac profiles. The boundaries of the 718 
significantly differentially acetylated peak region are highlighted in red. 719 
 720 
Figure 7. AD-associated differential expression of transcripts annotated to 721 
differentially-acetylated peaks. We quantified the expression of selected cortex-expressed 722 
genes located proximal to top-ranked differentially-acetylated peaks in an extended set of 95 723 
entorhinal cortex samples. The abundance of each test gene was determined by relative 724 
quantification to the geometric mean of the five housekeeping genes (ACTB, EIF4A2, 725 
GAPDH, SF3A1, and UBC) incorporating experimental variables (RNA isolation batch, RIN 726 
score) as covariates. Shown for each gene is the relative expression (log2 fold ratio) in AD 727 
cases (n = 67 biologically independent samples) and controls (n = 28 biologically 728 
independent samples). The center line of the boxplot shows the median, the outer hinges 729 
correspond to the 25th and 75th percentile, respectively, and the whiskers extend to the most 730 
extreme observed value within 1.5 times the interquartile range (IQR) from the two hinges. 731 
For each of the genes shown, we identified a significant difference between groups in the 732 
direction predicted from our H3K27ac ChIP-seq data. The expression of RGCC, PIM3, 733 
PSEN1 and CR1 - located proximal to hyperacetylated peaks - was found to be significantly 734 
up-regulated in AD cases (linear regression, RGCC: n = 94 biologically independent 735 
samples, P = 0.002, β = 0.44, F(3,90) = 12.09; PIM3: n = 95 biologically independent 736 
samples, P = 9.52E-05, β = 0.57, F(3,92) = 25.78; PSEN1: n = 95 biologically independent 737 
samples, P = 4.91E-04, β = 0.45, F(3,92) = 4.98; CR1: n = 91 biologically independent 738 
samples, P = 0.001, β = 0.72, F(3,88) = 5.89). The expression of GPR22 and KMO - located 739 
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proximal to hypoacetylated peaks - was found to be significantly down-regulated in AD 740 
cases (GPR22: n = 95 biologically independent samples, P = 0.005, β = -0.71, F(3,91) = 741 
2.88; KMO: n = 60 biologically independent samples, P = 0.006, β = -0.96, F(3,57) = 2.77). 742 
  743 
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Table 1. Differential H3K27ac associated with AD. Shown are the ten top-ranked hyper- 
and hypoacetylated H3K27ac peaks, controlling for age at death and neuronal proportion 
estimates derived from DNA methylation data. Genes were annotated to each H3K27ac 
peak using GREAT50. The expression of underlined genes was quantified using qPCR. 
Rank Chr Position (start – end) P value  FDR Log 
FC 
GREAT 
annotated genes 
Hyperacetylated peaks 
1 13 112101248-112102698 2.04E-08 0.002 0.93 SOX1, TEX29 
2 13 42094789-42095919 6.31E-08 0.003 0.92 RGCC, VWA8 
3 22 50342521-50343567 1.02E-07 0.003 0.93 PIM3, CRELD2 
4 5 640598-642071 1.36E-07 0.003 0.88 CEP72, TPPP 
5 8 145180336-145181125 2.72E-07 0.004 1.12 FAM203A, 
MAF1 
6 17 19665361-19666514 3.86E-07 0.004 0.77 ALDH3A1, 
ULK2 
7 1 9392591-9393233 5.25E-07 0.004 0.83 SLC25A33, 
SPSB1 
8 17 19619421-19620832 5.43E-07 0.004 0.80 SLC47A2 
9 17 43925717-43927482 7.01E-07 0.005 0.71 MAPT, SPPL2C 
10 1 9341867-9342320 8.55E-07 0.005 1.05 SPSB1, H6PD 
Hypoacetylated peaks 
1 7 64011549-64012825 1.66E-08 0.002 -0.86 ZNF680, 
ZNF736 
2 21 29827289-29828201 5.70E-08 0.003 -0.85 N6AMT1 
3 1 179175226-179176637 7.03E-08 0.003 -0.70 ABL2, TOR3A 
4 1 241397411-241399621 9.73E-08 0.003 -0.75 GREM2, RGS7 
5 12 13627258-13629064 1.46E-07 0.003 -0.80 EMP1, GRIN2B 
6 8 3964265-3966191 2.44E-07 0.004 -0.57 CSMD1 
7 4 74088063-74089559 2.52E-07 0.004 -0.68 COX18, 
ANKRD17 
8 6 166401119-166402753 2.85E-07 0.004 -1.06 SDIM1, T 
9 7 107111795-107113029 2.88E-07 0.004 -0.90 DUS4L, GPR22 
10 1 241694436-241695782 3.37E-07 0.004 -0.71 KMO 
 744 
  745 
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Online Methods 746 
Samples  747 
Post-mortem brain samples from 95 individuals - 67 with advanced AD neuropathology and 748 
28 neuropathology-free brain samples - were provided by the MRC London 749 
Neurodegenerative Disease Brain Bank (http://www.kcl.ac.uk/ioppn/depts/cn/research/MRC-750 
London-Neurodegenerative-Diseases-Brain-Bank/MRC-London-Neurodegenerative-751 
Diseases-Brain-Bank.aspx). No statistical methods were used to pre-determine sample 752 
sizes but our sample sizes are similar to, or larger than, those reported in previous brain 753 
ChIP-seq analyses17,48. Ethical approval for the study was provided by the NHS South East 754 
London Research Ethics Committee (REC) 3.  Subjects were approached in life for written 755 
consent for brain banking, and all tissue donations were collected and stored following legal 756 
and ethical guidelines (NHS reference number 08/MRE09/38; the HTA license number for 757 
the LBBND brain bank is 12293). Samples for this ChIP-seq study were selected from a 758 
larger collection of post-mortem entorhinal cortex (Brodmann area (BA) 28/34) samples, 759 
based on Braak staging, a standardized measure of neurofibrillary tangle burden determined 760 
at autopsy51. We prioritized cases with high Braak staging and controls with lower Braak 761 
scores (Supplementary Table 1). All samples were dissected by trained specialists, snap-762 
frozen and stored at −80 °C. SNP array data from each donor generated using the Illumina 763 
Infinium HumanCore-24 SNP array was merged with HapMap Phase 3 data and genetic 764 
principal components (PCs) were calculated with GCTA52 to confirm the ethnicity of each 765 
sample as European (Supplementary Fig. 1). A detailed list of demographic and sample 766 
data for each individual included in the final analyses is provided in Supplementary Table 767 
1. 768 
 769 
Chromatin immunoprecipitation (ChIP) 770 
Tissue from a subset of 27 individuals with advanced AD neuropathology and 27 individuals 771 
with minimal neuropathology were selected for our ChIP-seq analyses. Samples were 772 
randomized at all experimental stages, with processing batches comprising an equal number 773 
of AD cases and controls. Samples were labeled with anonymized ID codes and processed 774 
in batches, blinding disease status from the experimenter/analyst for individual samples. 775 
Chromatin immunoprecipitation was performed using the iDeal ChIP-Seq kit for Histones 776 
(Cat# C01010051, Diagenode, Seraing, Belgium) as detailed below, using the standard kit 777 
components unless otherwise stated. 30 mg of entorhinal cortex tissue was homogenized 778 
with a dounce homogenizer in 1 mL ice-cold phosphate buffered saline (PBS) buffer with 779 
protease inhibitor cocktail (PIC). The suspension was centrifuged at 4,000 rpm for 5 minutes 780 
at 4°C, discarding the supernatant. The pellets were resuspended in 1 mL PBS containing 781 
1% formaldehyde, rotating at room temperature for 8 minutes. The cross-linking process 782 
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was terminated by adding 100 μL glycine solution, followed by 5 minutes of rotation. After 5 783 
minutes of centrifugation at 4,000 rpm and 4°C, the pellet was washed twice with ice-cold 784 
PBS (suspending the pellet in 1 mL PBS with PIC, centrifuging for 5 minutes at 4,000 rpm 785 
and 4°C, and discarding the supernatant), then lysed in 10 mL ice-cold lysis buffer iL1 and 786 
iL2, sequentially (re-suspending the pellet in 10 mL lysis buffer, mixing gently for 10 minutes 787 
at 4°C, centrifuging for 5 minutes at 4,000 rpm and 4°C, and discarding the supernatant). 788 
The cross-linked lysate was suspended in 1.8 mL shearing buffer iS1 containing PIC and 789 
sonicated in aliquots of 300 μL for 10 cycles (30 seconds on/off each cycle) on a Bioruptor 790 
Pico (Diagenode, Seraing, Belgium). After shearing, samples were transferred to 1.5 mL 791 
microcentrifuge tubes and centrifuged at 14,000 rpm for 10 minutes, collecting the 792 
supernatant, containing the soluble sheared chromatin with fragments of an average size 793 
range of 100-1000bp as visualized by agarose gel electrophoresis (Supplementary Fig. 794 
23).  795 
 796 
Immunoprecipitation was performed on the SX-8G IP-Star robot (Diagenode, Seraing, 797 
Belgium), following the manufacturer’s protocol. All samples were immunoprecipitated with 798 
H3K27ac polyclonal antibody (Diagenode, Seraing, Belgium) (Cat #C15410196, lot number: 799 
A1723-0041D). This antibody has been validated for ChIP-seq applications (validation data 800 
from Diagenode available at: https://www.diagenode.com/en/p/h3k27ac-polyclonal-antibody-801 
premium-50-mg-18-ml). In addition, a randomly selected subgroup of 12 samples – 6 cases 802 
and 6 controls – were immunoprecipitated with rabbit IgG antibody (iDeal ChIP-seq kit) as 803 
negative control. 1-1.5 μL of H3K27ac or IgG antibody were first mixed with 98.5-99 μL ChIP 804 
buffer iC1, 0.5 μL PIC and 4 μL of 5% bovine serum albumin (BSA), which was incubated 805 
with magnetic beads for 3 hours at 4°C. Next the antibody conjugate was added to 180 μL 806 
chromatin for overnight (15h) immunoprecipitation at 4°C in an immunoprecipitation mix also 807 
containing 20 μL ChIP buffer iC1, 1 μL PIC and 4 μL of 5% BSA. After immunoprecipitation, 808 
the beads were re-suspended in in 100 μL elution buffer iE1, to which 4 μL elution buffer iE2 809 
was added. Cross-link reversal was performed on a PCR thermoblock for 4 hours at 65°C. 810 
DNA was extracted using Micro ChIP DiaPure columns (Diagenode, Cat No C03040001, 811 
Seraing, Belgium) according to the manufacturers protocol, eluting the DNA from the column 812 
matrix in 30 μL DNA elution buffer (MicroChIP DiaPure columns; Diagenode, Cat 813 
#C03040001, Denville, NJ, USA). Quantitative PCR, using 1% input DNA, was used to 814 
confirm specific enrichment of H3K27ac at positive control genes (IEF4A2 and GAPDH) but 815 
not at negative control genes (MBex2 and TSH2b; all primers were provided by Diagenode).  816 
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 817 
Illumina short-read sequencing 818 
Libraries were prepared using the MicroPlex Library Preparation kit v2 (Diagenode, Cat 819 
#C05010013, Seraing, Belgium) on a SX-8G IP-Star robot according to the manufacturer’s 820 
protocol. DNA concentrations were measured with Qubit dsDNA HS Assay Kits (Invitrogen, 821 
Cat# Q32851, Carlsbad, CA, USA) on the Qubit 2.0 Fluorometer (Invitrogen) and library 822 
fragment profiles generated on the Agilent 2100 BioAnalyzer using Agilent High Sensitivity 823 
DNA kits (Agilent Technologies, Cat# 5067-4626, Santa Clara, CA, USA). Following our 824 
stringent quality-control filtering, 7 samples were excluded from sequencing based on poor 825 
qPCR results after immunoprecipitation or low library concentration. The remaining 47 826 
samples (from 24 cases and 23 controls) were sequenced on an Illumina HiSeq-2500 using 827 
single-end sequencing and a read length of 50bp. ChIP-seq data are available to download 828 
from GEO (accession number GSE102538). 829 
 830 
Data pre-processing and quality control  831 
Global sample anomalies were ruled out using fastqc53 summary measures.  All fastq files 832 
were aligned to the Homo sapiens reference genome (hg19, Broad Institute) using Bowtie54. 833 
The output SAM files were converted to binary (BAM) format. All BAM files were sorted and 834 
indexed using samtools55. PCR duplicates were removed using Picard 835 
(http://broadinstitute.github.io/picard/). Samtools was used to additionally remove non-836 
uniquely mapped reads as well as reads with a sequencing quality score q < 30. Final read 837 
counts after QC for all 47 samples are shown in Supplementary Fig. 2. On average, we 838 
obtained 30,032,623 reads per sample (SD = 10,638,091; range = 10,910,000-53,770,000) 839 
and individual read counts did not associate with disease status (Welsh two-sample t-test, 840 
two-sided, n = 47 biologically independent samples, P = 0.93, average read count 841 
difference: 260,673, 95%-CI: -6,602,319-6,080,972, t(43.85) = -0.08). For each sample we 842 
also calculated standard ENCODE ChIP-seq quality metrics (see 843 
https://genome.ucsc.edu/ENCODE/qualityMetrics.html#definitions): uniquely mappable 844 
reads (UMR), normalized stand cross-correlation (NSC), relative strand cross-correlation 845 
(RSC) and nonredundancy fraction (NrF) as well as the percentage of reads in peaks. These 846 
quality metrics were included as post-hoc covariates in our analyses.  847 
 848 
Peak calling and read counts 849 
All filtered BAM files were merged into one grouped file and converted to tagAlign format 850 
using bedtools56. Peaks were called on this merged file using MACS257, keeping all 851 
duplicates, since duplicates were removed from each sample previously and any remaining 852 
duplicates would result from the same read occurring in more than one sample. From the 853 
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resulting peaks those located in unmapped contigs and mitochondrial DNA were filtered out 854 
as well as peaks that did not meet a significance threshold of P < 1.00E-07 for peak calling. 855 
The bed file of peaks was converted to gff format using awk and R, and reads for each 856 
individual sample were generated using HTSeq58. Final filtering was performed using the 857 
Bioconductor package EdgeR59, excluding peaks with fewer than 2 samples showing at least 858 
1 read per million, resulting in a total of 182,065 peaks to be tested. Principal components 859 
analysis (PCA) in R using DESeq260 confirmed that the epigenetically predicted gender was 860 
identical to the recorded one (Supplementary Fig. 6), with load on the first two principal 861 
components not related to disease status. Analysis scripts related to this project are 862 
available to download from: https://epigenetics.essex.ac.uk/AD_H3K27ac/. 863 
 864 
Peak validation  865 
We validated the 182,065 union peaks in two ways. First, we obtained the locations of 866 
H3K27ac peaks called in the cortex (BA9) and cerebellum from a recent paper by Sun and 867 
colleagues17. Second, we downloaded H3K27ac profiles produced by the NIH Roadmap 868 
Epigenomics Consortium18 from the Gene Expression Omnibus (GEO; 869 
https://www.ncbi.nlm.nih.gov/geo) for multiple cell-/tissue-types including several brain 870 
regions (mid frontal lobe (GSM773015), inferior temporal gyrus (GSM772995), middle 871 
hippocampus (GSM773020), substantia nigra (GSM997258), cingulate gyrus (GSM773011), 872 
H1-derived neuronal progenitor cells (HDNPs, GSM753429), lung (GSM906395), liver 873 
(GSM1112808) and skeletal muscle (GSM916064)). The downloaded files were in bed 874 
format, on which we performed peak calling using MACS2 and the same specifications as 875 
described for our own samples, discounting any duplicate reads. We calculated the overlap 876 
between each peak set and our peaks by quantifying the percentage of peaks from the 877 
external sample overlapping our peaks using the Bioconductor package GenomicRanges61. 878 
In addition, using the 182,065 entorhinal cortex (EC) peak regions identified in this study, we 879 
generated read counts on raw H3K27ac data from cerebellum, prefrontal cortex (PFC) and 880 
temporal cortex (TC) published by Sun et al. (2016)17. Counts per million (CPM) at all peaks 881 
were scaled and centered prior to principal components analysis.  882 
 883 
Differential peak calling  884 
We used the quasi-likelihood F test62 in EdgeR59 to analyse peak differences between AD-885 
cases and controls, allowing us to correct for potential confounders in the analysis of 886 
differential peaks. Our analyses accounted for additional phenotypic variation across the 887 
samples, including age at death and neuronal proportion estimates based on DNA 888 
methylation profiles from the Illumina 450K HumanMethylation Array from the same 889 
samples, which were calculated using the CETS R package47. We imputed the median 890 
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CETS estimate for one individual with missing DNA methylation data. Age at death and 891 
CETS estimates were converted to five-level factors using the R function cut() specifying five 892 
breaks prior to being included as covariates in the EdgeR differential peak calling method. 893 
This function divides a numerical variable into five bins of equal length, determined by the 894 
range of the variable. The distribution of the age and CETS variable (including the imputed 895 
individual) with the respective bins of the factor variables are shown in Supplementary Fig. 896 
5. We next calculated normalization factors based on sample-specific library compositions 897 
and estimated both sample and peak-specific dispersions, specifically for a generalized 898 
linear model controlling for factorized CETS estimates and age at death. The quasi-899 
likelihood F-test was conducted after fitting a quasi-likelihood model62 using the glmQLFit() 900 
and glmQLFTest() functions respectively. Effect sizes are reported as log fold change, a 901 
standard measure for quantifying sequencing read count differences between different 902 
conditions. Log fold change refers to the log2-transformed ratio of normalized read counts 903 
between cases and controls, with positive values indicating higher normalized read counts in 904 
AD samples. As further sensitivity analyses, we repeated the differential peak calling model, 905 
covarying additionally for i) sex, ii) expression of cell-type specific marker genes for the five 906 
major brain cell-types (CD34, CD68, ENO2, GFAP and OLIG2 – see Online Methods: Gene 907 
expression analyses) individually and combined, and iii) five ChIP-seq quality metrics (UMR, 908 
RSC, NSC, NrF and percent reads in peaks – see Online Methods: Data pre-processing and 909 
quality control). P values in each of the additional control models at all 4,162 differentially 910 
acetylated peaks from our main model are reported in Supplementary Tables 4 and 5. The 911 
bedtools program genomecov was used to generate coverage value scaled by library size 912 
and the number of samples per group, for each sample. These were then joined using 913 
unionbedg and summed using a Perl script to produce a weighted mean for each variable 914 
sized interval defined by read overlaps and used to generate UCSC genome browser tracks 915 
(accessible at https://epigenetics.essex.ac.uk/AD_H3K27ac/). 916 
 917 
Genomic annotation and enrichment analyses  918 
Peaks were annotated to genes using the Genomic Region Enrichment and Annotation 919 
Tools (GREAT)50, using the basal plus extension option and assigning genes to regulatory 920 
regions within 5kb upstream and 1kb downstream of the transcription start site (proximal) or 921 
up to 1000kb for distal interactions. In addition, we performed enrichment analyses 922 
calculating statistical enrichments for ontological annotation (gene ontologies for molecular 923 
function, biological processes63 and human diseases64). Functional enrichment analyses 924 
were conducted for significantly hyper- and hypoacetylated peaks (FDR < 0.05) separately, 925 
using the basal plus extension option. Significance in the enrichment test is based on a 926 
hypergeometric test of genes annotated to the test set (hyper-/ hypoacetylated peaks) 927 
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compared to the background set of genes annotated to all 182,065 peaks called across all 928 
samples. Results presented in Supplementary Fig. 18 are restricted to the top five non-929 
redundant enrichments (separated by at least two nodes in the local directed acyclic graph 930 
visualizing the hierarchy of enriched terms from a single ontology) associated with at least 931 
three genes in the test set for the ontology categories biological process, molecular function, 932 
and disease ontology and we show full enrichments across all categories in Supplementary 933 
Tables 11-16. Enrichments for familial AD and AD pathology genes were calculated using a 934 
one-tailed hypergeometric test. 935 
 936 
Motif enrichment analysis  937 
Motif analysis was performed using the Regulatory Sequence Analysis Tools suite 938 
(RSAT)65,66, available at http://rsat.sb-roscoff.fr. Peak sequences were reduced to 1500bp on 939 
each side of the peak centre, and motif discovery was conducted on 6 and 7mer 940 
oligonucleotides, comparing the statistically enriched sequences with known transcription 941 
factor motifs from JASPAR67 (core nonredundant vertebrates) and Homer68 (Human TF 942 
motifs).  Enrichments were computed using a binomial test, relative to the background peak 943 
sequences (n = 182,065 peaks) for significantly hyper- and hypoacetylated peaks (FDR < 944 
0.05). 945 
 946 
Integration of H3K27ac ChIP-seq data with results from AD genome-wide association 947 
studies (GWAS) 948 
The summary statistics for the stage 1 GWAS from Lambert and colleagues7 were 949 
downloaded from http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php. 950 
These results were clumped (p1 = 1e-4; p2 = 1e-4, r2 =0.1, window = 3000kb) using plink69, 951 
which collapses multiple correlated signals (due to linkage disequilibrium (LD)) into regions 952 
which contain independent signals. LD relationships were inferred from a reference 953 
genotype dataset (Phase 1) from another study70. Neighbouring regions located within 954 
250kb of each other on the same chromosome were subsequently merged. After clumping, 955 
each region was assigned the minimum P value for all SNPs contained in the region (from 956 
Lambert et al), and regions were then filtered to the genome-wide significance threshold (P < 957 
5.0E-08). This yielded 11 LD blocks for the genome-wide significant findings from Lambert et 958 
al., which were then overlapped with our AD-associated differentially acetylated peaks using 959 
the Bioconductor package GenomicRanges61. To estimate the proportion of AD heritability 960 
attributable to H3K27ac peaks in adult brain, we performed partitioned heritability analysis 961 
using the LD Score regression software (https://github.com/bulik/ldsc)71,72. LD scores were 962 
generated based on custom annotations derived from our ChIP-Seq data and 1000 963 
genomes reference data (downloaded alongside the software from 964 
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https://data.broadinstitute.org/alkesgroup/LDSCORE/). Genetic variants were annotated to 965 
our ChIP-seq peaks and heritability statistics calculated using the publicly available GWAS 966 
results from Lambert et al7. Enrichment statistics were calculated as the proportion of 967 
heritably divided by the proportion of SNPs for variants annotated to H3K27ac peaks.  968 
 969 
Gene expression analysis 970 
30-50mg of frozen entorhinal cortex tissue from 95 individuals [67 high neuropathology; 28 971 
low neuropathology] was homogenized with Qiazol (Qiagen, Valencia, CA, USA) as per the 972 
manufacturer’s instructions before being run through a QIAshredder (Qiagen, Valencia, CA, 973 
USA). Total RNA was extracted using the Qiagen RNeasy column purification system and 974 
treated with DNase I. The Agilent 2200 TapeStation was used to check the quality and 975 
concentration of the extracted RNA samples. Complementary DNA (cDNA) was reverse 976 
transcribed using the Invitrogen VILO cDNA synthesis kit (Life Technologies) in 20μL 977 
reactions according to manufacturer’s instructions. After stringent QC, quantitative RT–PCR 978 
was performed in duplicate using the QuantStudio 12K Flex (Applied Biosystems) in 979 
conjunction with the TaqMan low-density array (TLDA) platform using off the shelf pre-980 
optimized assays targeting i) genes located proximal to top-ranked AD-associated H3K27ac 981 
peaks (ANKRD17, GPR22, KMO, RGCC, PIM3, and ZNF680), ii) additional genes 982 
previously implicated in AD etiology and/or neuropathology and also annotated to significant 983 
differentially-acetylated peaks (APP, CR1, MAPT, PSEN1, PSEN2, and TOMM40), iii) genes 984 
expressed in the major brain cell types to control for cell-type heterogeneity (ENO2 985 
(neurons), OLIG2 (oligodendrocytes), GFAP (astrocytes), CD68 (microglia) and CD34 986 
(endothelial cells), and iv) five house-keeping genes (ACTB, EIF4A2, GAPDH, SF3A1, and 987 
UBC) identified as being most stably expressed in the brain using GeNORM (Primer Design, 988 
Southampton, UK). A full list of qPCR assays used is given in Supplementary Table 21. 989 
PCR cycling conditions were 50°C for 2 min, 94.5°C for 10 min and 45 cycles of 97°C for 990 
15s and 60°C for 1 min. We undertook stringent QC of raw qPCR data, removing samples 991 
where there was high variability between duplicates (Ct > 0.5). The abundance of each test 992 
gene was determined by the comparative Ct method73, expressed relative to the geometric 993 
mean of the five house-keeping genes quantified in parallel. Data were log2transformed to 994 
ensure normal distribution, and presented as a fold-difference in expression of AD cases 995 
relative to controls. Associations of gene expression were assessed by linear regression of 996 
deltaCt against disease status, incorporating experimental variables (RNA isolation batch, 997 
RIN score) as covariates. We tested for an association between H3K27ac and gene 998 
expression using EdgeR as described above, including RNA isolation batch and RIN score 999 
as covariates. 1000 
 1001 
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Integrative analysis with DNA methylation and hydroxymethylation  1002 
DNA methylation and hydroxymethylation data was available (A. Smith et al, unpublished) 1003 
from entorhinal cortex DNA for 42 of the samples profiled using ChIP-seq in this study. DNA 1004 
methylation and hydroxymethylation profiles were generated on the Illumina Infinium 1005 
HumanMethylation450 BeadChip (Illumina Inc., CA, USA) (“Illumina 450K array”) using the 1006 
TrueMethyl Array kit (Cambridge Epigenetix, Cambridge, UK). Profiles for both modifications 1007 
were pre-processed, normalized and filtered according to a stringent standardised quality 1008 
control pipeline, as described previously43 using the wateRmelon74 package in R. We 1009 
identified probes on the array within 1kb of differentially acetylated peaks (FDR < 0.05) using 1010 
the Bioconductor package GenomicRanges61. 268,477 peak-probe pairs (comprising of 1011 
232,233 unique 450K array probes and 62,714 (34.45% of total) unique H3K27ac peaks). Of 1012 
these, a total of 1,649 of the 4,162 FDR significant differentially acetylated peaks were 1013 
located within 1kb of at least one CpG probe on the array, with a total of 6,838 probes 1014 
mapping to the 1kb neighbourhood of these 1,649 peaks. For each CpG-peak pair we 1015 
correlated the log fold change in H3K27ac between AD cases and controls to the difference 1016 
in DNA methylation or hydroxymethylation between AD cases and controls estimated from a 1017 
linear model controlling for the same covariates as in the differential acetylation analysis. We 1018 
examined patterns of DNA methylation and hydroxymethylation across probes in the vicinity 1019 
of AD hyper- and hypoacetylated peaks, as well as those in vicinity of all background peaks 1020 
and the whole microarray background using Welsh two sample t-tests. Finally, we analysed 1021 
the correlation of acetylation and DNA methylation at all peak-probe pairs using a Pearson’s 1022 
product-moment correlation between H3K27ac counts per million and DNA methylation 1023 
(normalized betas). 1024 
 1025 
Statistical analysis 1026 
For the ChIP-seq analysis we used the quasi-likelihood F test62 in EdgeR59. Our analyses 1027 
accounted for additional phenotypic variation across the samples, including age at death and 1028 
neuronal proportion estimates based on DNA methylation profiles from the Illumina 450K 1029 
HumanMethylation Array from the same samples, which were calculated using the CETS R 1030 
package47. Peaks were considered differentially acetylated at a false discovery rate (FDR) < 1031 
0.05 (controlled by Benjamini-Hochberg for n = 182,065 tests). ChIP-seq data is summarized 1032 
as read counts per peak and sample. EdgeR assumes a negative binomial distribution, 1033 
which is the most appropriate distribution for overdispersed count data, such as sequencing 1034 
read counts in features. The data distribution at each of the 182,065 peaks was not formally 1035 
tested. Associations of gene expression were assessed by linear regression of deltaCt 1036 
against disease status, incorporating experimental variables (RNA isolation batch, RIN 1037 
score) as covariates. We tested for an association between H3K27ac and gene expression 1038 
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using EdgeR as described above, including RNA isolation batch and RIN score as 1039 
covariates. Given that the statistical software R cannot report arbitrarily small P values due 1040 
to computational memory constraints, we report P < 1.00E-50 whenever the software output 1041 
showed P = 0 or a P value less than 1.00E-50. 1042 
 1043 
Life Sciences Reporting Summary 1044 
Further information on experimental design is available in the Life Sciences Reporting 1045 
Summary.  1046 
 1047 
Data availability 1048 
Raw data has been deposited in GEO under accession number GSE102538. Browsable 1049 
UCSC genome browser tracks of our processed H3K27ac ChIP-seq data are available as a 1050 
resource at: https://epigenetics.essex.ac.uk/AD_H3K27ac/. 1051 
 1052 
Code availability 1053 
Analysis code is given in Supplementary Software and also available to download from 1054 
https://epigenetics.essex.ac.uk/AD_H3K27ac/code/index.html.  1055 
 1056 
  1057 
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